GLP-1 medications for weight loss significantly impact large employers’ budgets, with Bank of America CEO Brian Moynihan noting the company spends over $250 million annually on these drugs, accounting for 13% of total healthcare spending. Despite the high costs, BofA plans to maintain coverage, citing both short- and long-term benefits for its workforce and the bank.
Michael Siluk/Getty ImagesGLP-1 medications for weight loss are biting into large employers’ budgets, and in some cases coverage has become financially untenable, recent examples sugg
est.Bank of America CEO Brian Moynihan recently said that the company is spending more than $250 million annually on GLP-1s, representing 13% of its total healthcare spending. BofA has no plans to drop coverage, though, as Moynihan cited both short- and long-term benefits for the workforce and the bank, which anticipates
https://www.hr-brew.com/stories/large-employers-glp-1-medications?utm_source=&utm_medium=syndication&utm_campaign=feed